Crohn's and Colitis Foundation of Canada and AbbVie Corporation Awarding Scholarships to Empower Seven Incredible Youth with

Crohn's and Colitis Foundation of Canada and AbbVie Corporation Awarding 
Scholarships to Empower Seven Incredible Youth with IBD 
Nominations now being accepted for Second Annual Scholarship Program that 
rewards remarkable students living with Crohn's disease and ulcerative colitis. 
TORONTO, March 21, 2013 /CNW/ - Canada has one of the highest reported 
prevalence of inflammatory bowel disease (IBD) in the world and 20-30% of 
people with IBD are diagnosed before the age of 20*. To support Canadian 
students living with IBD and raise awareness about this chronic disease, the 
AbbVie IBD Scholarship Program is accepting nominations from young people 
living with IBD. 
In partnership with the Crohn's and Colitis Foundation of Canada (CCFC), the 
AbbVie IBD Scholarship Program is designed to award students who are living 
well with IBD, and strive to sustain an optimal level of wellness allowing 
them to excel while inspiring others to do the same. Through an unrestricted 
educational grant by AbbVie, CCFC will extend seven (7) one-time scholarships 
of up to $5,000 CAN to students living with IBD who are entering into or are 
currently attending a post-secondary educational institution. Students of all 
ages are welcome to apply and the scholarship can be used for any Canadian 
post-secondary institution. 
"I am committed to living each day to the fullest and I'm so grateful to the 
CCFC and AbbVie for giving me the opportunity and inspiration to push harder 
and help me excel at my academic goals," says Clinton Shard, one of seven (7) 
2012 "gutsy" scholarship winners. "While the monetary scholarship provides 
an incentive, it also represents an investment in assisting students living 
with IBD and helping us achieve our dreams." 
Through initiatives such as the scholarship program, AbbVie aims to continue 
accelerating the recognition of the burden of IBD and help further the global 
dissemination of evolving approaches to better care for people living with IBD. 
"AbbVie is proud to partner again this year with CCFC for the AbbVie IBD 
Scholarship Program. This initiative is a great example of a partnership that 
makes a difference in people's lives," states Felipe Pastrana, General Manager 
of AbbVie Canada. "While our name, AbbVie, has changed - our commitment to the 
IBD community endures. Over the years, AbbVie has shown continued commitment 
to people living with IBD by helping organizations and health care providers 
alike better understand the impact of these diseases on people's lives. AbbVie 
recognizes the need for better disease diagnosis and monitoring to help 
improve the lives of millions of people affected by this chronic and 
debilitating disease." 
IBD Incidence Rates on the Rise
Inflammatory bowel disease, or IBD, is a group of disorders that causes the 
intestines to become inflamed and ulcerated. This is caused by an abnormal 
response of the body's immune system. 
A recent survey conducted by the CCFC found that 69 percent of people who had 
IBD when they were young were delayed in completing their post-secondary 
education. 89 percent who had IBD as a child felt that they could have 
achieved more at school without their disease. Since there is currently no 
known cure or cause, young people need strategies to achieve their best 
long-term health despite their diagnosis. 
Unfortunately, a majority of people living with IBD endure many challenges 
when it comes to their education. With intensive medical treatments, 
debilitating symptoms and lengthy hospital stays, keeping up with school can 
become extremely difficult. 
"Due to the isolating nature of the disease, people living with IBD too often 
miss out on the great life experiences many of us take for granted, including 
completing their education," says Dr. Kevin Glasgow, CCFC's Chief Executive 
Officer. "The AbbVie IBD Scholarship was born of the desire to support 
students with Crohn's and colitis and help empower them to continue their 
education and excel to their fullest potential. Our challenge is to find 
more youth like Clinton who are speaking out to help reduce the stigma 
associated with digestive disease. By telling their stories through the 
AbbVie IBD Scholarship Program, we know we can inspire many others to do the 
same at a time when advancing public understanding of IBD is needed most." 
The AbbVie IBD Scholarship Program - The A, B, C's
The AbbVie IBD Scholarship Program, in partnership with CCFC, is designed for 
applicants of any age entering into or attending a Canadian-based 
post-secondary institution. Applicants must be: 


    --  A legal and permanent resident of Canada;
    --  Diagnosed with inflammatory bowel disease by a physician;
    --  Seeking an associate's, undergraduate, or graduate degree from
        a Canadian university; college; or enrolled in a trade school
        educational program;
    --  Enrolled in or awaiting acceptance from a Canadian-based
        post-educational institution for the Fall semester of 2013; and
    --  A student who demonstrates academic aspiration and strives to
        sustain an optimal level of wellness in spite of their IBD,
        allowing them to excel to reach their personal and academic
        goals and inspiring others to do the same.

Visit www.ccfc.ca for full application details.

About CCFC
    --  The Crohn's and Colitis Foundation of Canada (CCFC) is a
        volunteer-based registered charity dedicated to finding the
        cure for Crohn's disease and ulcerative colitis and improving
        the lives of children and adults affected by these chronic
        diseases. To date, the CCFC has invested more than $76 million
        in research, making the foundation a world leader in
        non-governmental funding of IBD research.
    --  Canadian researchers funded by CCFC are conducting cutting edge
        research and are sustaining the hope for a cure worldwide.

For more information about CCFC, please visit www.ccfc.ca.

About AbbVie 
AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company 
formed in 2013 following separation from Abbott. AbbVie combines the focus and 
passion of a leading-edge biotech with the expertise and structure of a 
long-established pharmaceutical leader. The company's mission is to use its 
expertise, dedicated people and unique approach to innovation to develop and 
market advanced therapies that address some of the world's most complex and 
serious diseases. AbbVie aims to help patients live healthier lives and 
collaborate on sustainable healthcare solutions. AbbVie employs approximately 
21,000 people worldwide and markets medicines in more than 170 countries. For 
further information on the company and its people, portfolio and commitments, 
please visit www.abbvie.com or www.abbvie.ca. Follow @AbbVienews on Twitter or 
check out careers on our Facebook page.

* The Impact of Inflammatory Bowel Disease in Canada 2012 Final Report and 
Recommendations

In addition to CCFC's professional staff, CCFC has committed volunteers and 
members across Canada who are willing to speak with media about their 
experience with IBD. If you would like to speak with one of our volunteers, or 
for more information, please contact Ive Balins or Adriana Lurz at Strategic 
Objectives.

CCFC:Tel: (416) 366-7735. Fax: (416) 366-2295. 
Email:ibalins@strategicobjectives.com AbbVie:Tel: (514) 717-3764. Fax: 
(514) 832-7846. Email:murie.haraoui@abbvie.com

SOURCE: Crohn's and Colitis Foundation of Canada (CCFC)

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/March2013/21/c6739.html

CO: AbbVie
ST: Ontario
NI: HEA BTC MTC * ECOSURV 

-0- Mar/21/2013 09:59 GMT


 
Press spacebar to pause and continue. Press esc to stop.